164 related articles for article (PubMed ID: 16424035)
1. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.
Hoeflich KP; Gray DC; Eby MT; Tien JY; Wong L; Bower J; Gogineni A; Zha J; Cole MJ; Stern HM; Murray LJ; Davis DP; Seshagiri S
Cancer Res; 2006 Jan; 66(2):999-1006. PubMed ID: 16424035
[TBL] [Abstract][Full Text] [Related]
2. Inducible BRAF suppression models for melanoma tumorigenesis.
Hoeflich KP; Jaiswal B; Davis DP; Seshagiri S
Methods Enzymol; 2008; 439():25-38. PubMed ID: 18374154
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
4. BRAF is a therapeutic target in aggressive thyroid carcinoma.
Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
[TBL] [Abstract][Full Text] [Related]
5. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
King AJ; Patrick DR; Batorsky RS; Ho ML; Do HT; Zhang SY; Kumar R; Rusnak DW; Takle AK; Wilson DM; Hugger E; Wang L; Karreth F; Lougheed JC; Lee J; Chau D; Stout TJ; May EW; Rominger CM; Schaber MD; Luo L; Lakdawala AS; Adams JL; Contractor RG; Smalley KS; Herlyn M; Morrissey MM; Tuveson DA; Huang PS
Cancer Res; 2006 Dec; 66(23):11100-5. PubMed ID: 17145850
[TBL] [Abstract][Full Text] [Related]
6. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
Sala E; Mologni L; Truffa S; Gaetano C; Bollag GE; Gambacorti-Passerini C
Mol Cancer Res; 2008 May; 6(5):751-9. PubMed ID: 18458053
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis.
Zhao Y; Zhang Y; Yang Z; Li A; Dong J
Biochem Biophys Res Commun; 2008 Jun; 370(3):509-13. PubMed ID: 18402768
[TBL] [Abstract][Full Text] [Related]
8. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
9. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
11. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
12. Narrative review: BRAF opens the door for therapeutic advances in melanoma.
Flaherty KT
Ann Intern Med; 2010 Nov; 153(9):587-91. PubMed ID: 21041578
[TBL] [Abstract][Full Text] [Related]
13. Regulation of ERK3/MAPK6 expression by BRAF.
Hoeflich KP; Eby MT; Forrest WF; Gray DC; Tien JY; Stern HM; Murray LJ; Davis DP; Modrusan Z; Seshagiri S
Int J Oncol; 2006 Oct; 29(4):839-49. PubMed ID: 16964379
[TBL] [Abstract][Full Text] [Related]
14. Models and mechanisms in malignant melanoma.
Benjamin CL; Melnikova VO; Ananthaswamy HN
Mol Carcinog; 2007 Aug; 46(8):671-8. PubMed ID: 17570501
[TBL] [Abstract][Full Text] [Related]
15. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells.
Smith AG; Lim W; Pearen M; Muscat GE; Sturm RA
Pigment Cell Melanoma Res; 2011 Jun; 24(3):551-63. PubMed ID: 21362156
[TBL] [Abstract][Full Text] [Related]
16. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
[TBL] [Abstract][Full Text] [Related]
17. RKIP downregulates B-Raf kinase activity in melanoma cancer cells.
Park S; Yeung ML; Beach S; Shields JM; Yeung KC
Oncogene; 2005 May; 24(21):3535-40. PubMed ID: 15782137
[TBL] [Abstract][Full Text] [Related]
18. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
[TBL] [Abstract][Full Text] [Related]
19. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.
Sumimoto H; Imabayashi F; Iwata T; Kawakami Y
J Exp Med; 2006 Jul; 203(7):1651-6. PubMed ID: 16801397
[TBL] [Abstract][Full Text] [Related]
20. BRAF kinase in melanoma development and progression.
DeLuca AM; Srinivas A; Alani RM
Expert Rev Mol Med; 2008 Feb; 10():e6. PubMed ID: 18279546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
